WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bayer

The Bayer GroupBayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

www.bayer.com.

Bayer RSS Channel

Filters
List of articles in category Bayer
Title Published Date
Bayer Schering Pharma Enhances U.S. Research Strategy with New Innovation Center 18 May 2010
Bayer receives approval for its new oral contraceptive in the U.S. 17 May 2010
Bayer Schering Pharma Initiates Phase III Trial of Regorafenib 10 May 2010
Bayer Schering Pharma Initiates Phase III Trial of Regorafenib (BAY 73-4506) 10 May 2010
Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement 06 May 2010
Bayer achieves strong gains in sales and earnings 30 April 2010
Bayer HealthCare Marks 2010 World Hemophilia Day with EUR 250,000 Contribution 19 April 2010
Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII 26 January 2010
Bayer to discontinue the LIPLONG study 26 January 2010
Bayer Starts Phase III Trial with Florbetaben 01 December 2009
Bayer starts pivotal Phase III trial with Florbetaben 01 December 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer 23 October 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer 23 October 2009
Nexavar® Demonstrates 74 Percent Improvement in Progression-Free Survival 24 September 2009
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009 21 September 2009
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 21 September 2009
Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S. 03 September 2009
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF) 31 August 2009
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban 31 August 2009
Bayer acquires exclusive rights to Bioton's insulin SciLin® 10 July 2009
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End

Business & Industry

  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe
  • Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design

Research & Development

  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19
  • Scientists develop new biomimetic formulation for treating glioblastoma
  • SARS-CoV-2 hijacks nanotubes between neurons to infect them

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Bayer
  4. Four potential blockbusters in the Pharma pipeline

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.